CXCR5 and in situ carcinoma: In the combined groups, the majority of B cell subsets were positive for both BAFF-R and CXCR5 (Figure 4C) and most cells that were BAFF-R+ were also CXCR5+ in both CIS/MS patients and controls (Figure 4D).